Cargando…

Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository

BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants via routine datasets could provide a cost-effective alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilburn, Lucy Suzanne, Aresu, Maria, Banerji, Jane, Barrett-Lee, Peter, Ellis, Paul, Bliss, Judith Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702960/
https://www.ncbi.nlm.nih.gov/pubmed/29179731
http://dx.doi.org/10.1186/s13063-017-2308-6
_version_ 1783281620707442688
author Kilburn, Lucy Suzanne
Aresu, Maria
Banerji, Jane
Barrett-Lee, Peter
Ellis, Paul
Bliss, Judith Margaret
author_facet Kilburn, Lucy Suzanne
Aresu, Maria
Banerji, Jane
Barrett-Lee, Peter
Ellis, Paul
Bliss, Judith Margaret
author_sort Kilburn, Lucy Suzanne
collection PubMed
description BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants via routine datasets could provide a cost-effective alternative for ascertaining follow-up information required to evaluate disease outcomes. This project explores the potential for routine data to inform cancer trials, using, the historical National Cancer Data Repository (NCDR) for English NHS sites and, for validation, mature data available from the TACT trial. METHODS: Datasets were matched using patients’ NHS number, date of birth (dob) and name/initials. Demographics, clinical characteristics and outcomes were assessed for agreement and completeness. Overall survival was compared between NCDR and TACT. RESULTS: A total of 3151 patients underwent linkage; 3047 (96.7%) of which had matched records. Extensive cleaning was required for some registry data fields, e.g. cause of death, whilst others had large amounts of missing data, e.g. tumour size (22.1%). Other data had high levels of matching such as dob (99.6%) and date of death (89.6%). There was no evidence of differential survival rates (8-year survival: TACT = 75% (95% CI 73, 76); NCDR = 76% (95% CI 74, 77)). CONCLUSIONS: Data quality and completeness requires improvement before routine data could be used for RCTs. Introduction of new routine datasets, including COSD, is welcomed although reporting of disease-recurrence events remains a concern. Prospective validation of such datasets is required before RCTs can confidently switch patient follow-up to utilise routinely collected NHS-based data. TACT TRIAL REGISTRATION: Clinicaltrials.gov NCT00033683, registered on 9 April 2002; ISRCTN79718493, registered on 1 July 2001.
format Online
Article
Text
id pubmed-5702960
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57029602017-12-05 Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository Kilburn, Lucy Suzanne Aresu, Maria Banerji, Jane Barrett-Lee, Peter Ellis, Paul Bliss, Judith Margaret Trials Research BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants via routine datasets could provide a cost-effective alternative for ascertaining follow-up information required to evaluate disease outcomes. This project explores the potential for routine data to inform cancer trials, using, the historical National Cancer Data Repository (NCDR) for English NHS sites and, for validation, mature data available from the TACT trial. METHODS: Datasets were matched using patients’ NHS number, date of birth (dob) and name/initials. Demographics, clinical characteristics and outcomes were assessed for agreement and completeness. Overall survival was compared between NCDR and TACT. RESULTS: A total of 3151 patients underwent linkage; 3047 (96.7%) of which had matched records. Extensive cleaning was required for some registry data fields, e.g. cause of death, whilst others had large amounts of missing data, e.g. tumour size (22.1%). Other data had high levels of matching such as dob (99.6%) and date of death (89.6%). There was no evidence of differential survival rates (8-year survival: TACT = 75% (95% CI 73, 76); NCDR = 76% (95% CI 74, 77)). CONCLUSIONS: Data quality and completeness requires improvement before routine data could be used for RCTs. Introduction of new routine datasets, including COSD, is welcomed although reporting of disease-recurrence events remains a concern. Prospective validation of such datasets is required before RCTs can confidently switch patient follow-up to utilise routinely collected NHS-based data. TACT TRIAL REGISTRATION: Clinicaltrials.gov NCT00033683, registered on 9 April 2002; ISRCTN79718493, registered on 1 July 2001. BioMed Central 2017-11-23 /pmc/articles/PMC5702960/ /pubmed/29179731 http://dx.doi.org/10.1186/s13063-017-2308-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kilburn, Lucy Suzanne
Aresu, Maria
Banerji, Jane
Barrett-Lee, Peter
Ellis, Paul
Bliss, Judith Margaret
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository
title Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository
title_full Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository
title_fullStr Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository
title_full_unstemmed Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository
title_short Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository
title_sort can routine data be used to support cancer clinical trials? a historical baseline on which to build: retrospective linkage of data from the tact (cruk 01/001) breast cancer trial and the national cancer data repository
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702960/
https://www.ncbi.nlm.nih.gov/pubmed/29179731
http://dx.doi.org/10.1186/s13063-017-2308-6
work_keys_str_mv AT kilburnlucysuzanne canroutinedatabeusedtosupportcancerclinicaltrialsahistoricalbaselineonwhichtobuildretrospectivelinkageofdatafromthetactcruk01001breastcancertrialandthenationalcancerdatarepository
AT aresumaria canroutinedatabeusedtosupportcancerclinicaltrialsahistoricalbaselineonwhichtobuildretrospectivelinkageofdatafromthetactcruk01001breastcancertrialandthenationalcancerdatarepository
AT banerjijane canroutinedatabeusedtosupportcancerclinicaltrialsahistoricalbaselineonwhichtobuildretrospectivelinkageofdatafromthetactcruk01001breastcancertrialandthenationalcancerdatarepository
AT barrettleepeter canroutinedatabeusedtosupportcancerclinicaltrialsahistoricalbaselineonwhichtobuildretrospectivelinkageofdatafromthetactcruk01001breastcancertrialandthenationalcancerdatarepository
AT ellispaul canroutinedatabeusedtosupportcancerclinicaltrialsahistoricalbaselineonwhichtobuildretrospectivelinkageofdatafromthetactcruk01001breastcancertrialandthenationalcancerdatarepository
AT blissjudithmargaret canroutinedatabeusedtosupportcancerclinicaltrialsahistoricalbaselineonwhichtobuildretrospectivelinkageofdatafromthetactcruk01001breastcancertrialandthenationalcancerdatarepository